Chee Wei Ang

TL;DR: Different classes of nitroimidazoles that have been described in the literature in the past five years are summarized, from approved drugs and clinical candidates to examples undergoing preclinical or early stage development.

TL;DR: It is shown that pretomanid also possesses potent activity against Giardia lamblia and Entamoeba histolytica, thus expanding the therapeutic potential of nitroimidazooxazines and suggesting that promising subclasses of bicyclic nitroIMidazoles containing different core architectures have potential for further development.

TL;DR: Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated.

TL;DR: In this paper, mesoporous silica nanoparticles (MCM-41) were used as drug carriers for the delivery of poorly soluble antibacterial agents against tuberculosis in mice.

TL;DR: Derby derivatives with monocyclic side chains are selective against Mycobacterium tuberculosis, the causative agent of tuberculosis, but not active against other nontuberculosis mycobacteria.